You are here: Home » Current Affairs » News » Health
Business Standard

Trial starts to test new, potent HIV vaccine

The HIV Vaccine Trials Network (HVTN) is conducting the trial at 15 sites across South Africa. Results are expected in late 2020

Press Trust of India  |  Washington 

Trail starts to test new potent vaccine that may spell end for HIV

The largest and most advanced Human Immunodeficiency Virus (HIV) trial has been launched in to test the safety of a new experimental regimen that could prove to be the final nail in the coffin for the deadly virus.

The study, called 702, involves a new version of the only candidate ever shown to provide some protection against the virus.



It aims to enrol 5,400 men and women, making it the where more than 1,000 people become infected with every day.

"If deployed alongside our current armoury of proven prevention tools, a safe and effective could be the final nail in the coffin for HIV," said Anthony S Fauci, director of the US National Institute of Allergy and Infectious Diseases (NIAID).

"Even a moderately effective would significantly decrease the burden of disease over time in countries and populations with high rates of infection, such as South Africa," said Fauci.

The Trials Network (HVTN) is conducting the trial at 15 sites across South Africa. Results are expected in late 2020.

The experimental regimen being tested in the trial is based on the one investigated in the earlier RV144 clinical trial in Thailand led by the US Military Research Programme and the Thai Ministry of Health.

The Thai trial delivered landmark results in 2009 when it found for the first time that a could prevent infection, albeit modestly.

The new regimen aims to provide greater and more sustained protection than the RV144 regimen and has been adapted to the subtype that predominates in southern Africa, a region that includes the country of South Africa.

"The people of are making history by conducting and participating in the first efficacy study to build on the results of the Thai trial," said Glenda Gray, CEO of the South African Medical Research Council.

"has taken a devastating toll in South Africa, but now we begin a scientific exploration that could hold great promise for our country," Gray said, who is also a professor at the University of the Witwatersrand.

"If an were found to work in South Africa, it may dramatically alter the course of the pandemic," she said.

The experimental regimen tested in the Thai trial was found to be 31.2 per cent effective at preventing infection over the 3.5-year follow-up after vaccination.

In the 702 study, the design, schedule and components of the RV144 regimen have been modified in an attempt to increase the magnitude and duration of vaccine-elicited protective immune responses.

702 begins just months after interim results were reported for 100, its predecessor clinical trial, which found that the new regimen was safe for the 252 study participants and induced comparable immune responses to those reported in RV144.

RECOMMENDED FOR YOU

Trial starts to test new, potent HIV vaccine

The HIV Vaccine Trials Network (HVTN) is conducting the trial at 15 sites across South Africa. Results are expected in late 2020

The HIV Vaccine Trials Network (HVTN) is conducting the trial at 15 sites across South Africa. Results are expected in late 2020 The largest and most advanced Human Immunodeficiency Virus (HIV) trial has been launched in to test the safety of a new experimental regimen that could prove to be the final nail in the coffin for the deadly virus.

The study, called 702, involves a new version of the only candidate ever shown to provide some protection against the virus.

It aims to enrol 5,400 men and women, making it the where more than 1,000 people become infected with every day.

"If deployed alongside our current armoury of proven prevention tools, a safe and effective could be the final nail in the coffin for HIV," said Anthony S Fauci, director of the US National Institute of Allergy and Infectious Diseases (NIAID).

"Even a moderately effective would significantly decrease the burden of disease over time in countries and populations with high rates of infection, such as South Africa," said Fauci.

The Trials Network (HVTN) is conducting the trial at 15 sites across South Africa. Results are expected in late 2020.

The experimental regimen being tested in the trial is based on the one investigated in the earlier RV144 clinical trial in Thailand led by the US Military Research Programme and the Thai Ministry of Health.

The Thai trial delivered landmark results in 2009 when it found for the first time that a could prevent infection, albeit modestly.

The new regimen aims to provide greater and more sustained protection than the RV144 regimen and has been adapted to the subtype that predominates in southern Africa, a region that includes the country of South Africa.

"The people of are making history by conducting and participating in the first efficacy study to build on the results of the Thai trial," said Glenda Gray, CEO of the South African Medical Research Council.

"has taken a devastating toll in South Africa, but now we begin a scientific exploration that could hold great promise for our country," Gray said, who is also a professor at the University of the Witwatersrand.

"If an were found to work in South Africa, it may dramatically alter the course of the pandemic," she said.

The experimental regimen tested in the Thai trial was found to be 31.2 per cent effective at preventing infection over the 3.5-year follow-up after vaccination.

In the 702 study, the design, schedule and components of the RV144 regimen have been modified in an attempt to increase the magnitude and duration of vaccine-elicited protective immune responses.

702 begins just months after interim results were reported for 100, its predecessor clinical trial, which found that the new regimen was safe for the 252 study participants and induced comparable immune responses to those reported in RV144.
image
Business Standard
177 22

Trial starts to test new, potent HIV vaccine

The HIV Vaccine Trials Network (HVTN) is conducting the trial at 15 sites across South Africa. Results are expected in late 2020

The largest and most advanced Human Immunodeficiency Virus (HIV) trial has been launched in to test the safety of a new experimental regimen that could prove to be the final nail in the coffin for the deadly virus.

The study, called 702, involves a new version of the only candidate ever shown to provide some protection against the virus.

It aims to enrol 5,400 men and women, making it the where more than 1,000 people become infected with every day.

"If deployed alongside our current armoury of proven prevention tools, a safe and effective could be the final nail in the coffin for HIV," said Anthony S Fauci, director of the US National Institute of Allergy and Infectious Diseases (NIAID).

"Even a moderately effective would significantly decrease the burden of disease over time in countries and populations with high rates of infection, such as South Africa," said Fauci.

The Trials Network (HVTN) is conducting the trial at 15 sites across South Africa. Results are expected in late 2020.

The experimental regimen being tested in the trial is based on the one investigated in the earlier RV144 clinical trial in Thailand led by the US Military Research Programme and the Thai Ministry of Health.

The Thai trial delivered landmark results in 2009 when it found for the first time that a could prevent infection, albeit modestly.

The new regimen aims to provide greater and more sustained protection than the RV144 regimen and has been adapted to the subtype that predominates in southern Africa, a region that includes the country of South Africa.

"The people of are making history by conducting and participating in the first efficacy study to build on the results of the Thai trial," said Glenda Gray, CEO of the South African Medical Research Council.

"has taken a devastating toll in South Africa, but now we begin a scientific exploration that could hold great promise for our country," Gray said, who is also a professor at the University of the Witwatersrand.

"If an were found to work in South Africa, it may dramatically alter the course of the pandemic," she said.

The experimental regimen tested in the Thai trial was found to be 31.2 per cent effective at preventing infection over the 3.5-year follow-up after vaccination.

In the 702 study, the design, schedule and components of the RV144 regimen have been modified in an attempt to increase the magnitude and duration of vaccine-elicited protective immune responses.

702 begins just months after interim results were reported for 100, its predecessor clinical trial, which found that the new regimen was safe for the 252 study participants and induced comparable immune responses to those reported in RV144.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard